Plain-English translation of NCT06802887 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study that looks back at and follows patients with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who have been treated with Ustekinumab. Researchers will review your medical records and follow your care over time to understand how well this medication works for you and whether it helps control your symptoms long-term. The goal is to learn more about how this treatment performs in real-world patient care.
While this medication has been approved for treating inflammatory bowel disease, doctors want to understand how it performs when used in everyday clinical practice over months and years. This study will help fill in gaps about long-term effectiveness and safety in routine patient care.
You likely qualify if…
You likely don't qualify if…
As a participant, researchers will review your existing medical records from when you started this medication through your ongoing care. You may also be followed prospectively, meaning your care and outcomes will be monitored going forward. There are no special visits or procedures required beyond your regular doctor appointments — the study simply tracks how the medication is working as part of your normal treatment.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Italy
Enrollment target
~12 participants
Started
July 2021
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Paolo Gionchetti, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.